How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
SARS-Cov-2 Test Kits Market
- By Test Type: Molecular (RT-PCR) Test Kits, Antigen Test Kits, Antibody (Serology) Test Kits, Isothermal Amplification Test Kits
- By End User: Hospitals and Clinics, Diagnostic Laboratories, Point-of-Care Testing Centers, Home Testing, Research and Academic Institutes
- By Sample Type: Nasopharyngeal Swab, Oropharyngeal Swab, Saliva, Blood, Sputum
- By Technology Platform: Real-Time PCR, Lateral Flow Immunoassay, Enzyme-Linked Immunosorbent Assay (ELISA), CRISPR-based Assays, Loop-Mediated Isothermal Amplification (LAMP)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Molecular (RT-PCR) Test Kits leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the SARS-Cov-2 Test Kits Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Test Type 4
End User 5
Sample Type 5
Technology Platform 5
Companies profiled
Abbott Laboratories
Roche Diagnostics
Thermo Fisher Scientific
Siemens Healthineers
Becton Dickinson and Company (BD)
Quidel Corporation
Bio-Rad Laboratories
Hologic Inc.
Cepheid (a Danaher company)
PerkinElmer Inc.
F. Hoffmann-La Roche AG
GenMark Diagnostics
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Quidel Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Hologic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cepheid (a Danaher company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →PerkinElmer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →GenMark Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Luminex Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Mesa Biotech (a Thermo Fisher Scientific company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BioMérieux
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,996M by 2033 · 8.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Molecular (RT-PCR) Test Kits36.7
- Antigen Test Kits23.3
- Antibody (Serology) Test Kits22.7
- Isothermal Amplification Test Kits17.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,038M → $1,812M · 7.2%
Europe$723.3M → $1,521M · 9.7%
Asia Pacific$660.4M → $1,259M · 8.4%
Latin America$408.8M → $756.5M · 8.0%
Middle East and Africa$314.5M → $650.9M · 9.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.352026
8.362027
8.372028
8.402029
8.402030
8.412031
8.432032
8.432033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories21.7
- Roche Diagnostics24.6
- Thermo Fisher Scientific8.3
- Siemens Healthineers6.8
- Becton Dickinson and Company (BD)6.2
- Quidel Corporation4.3
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type28.0%
End User17.5%
Sample Type19.0%
Technology Platform35.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.2
- Europe25.4
- Asia Pacific21.0
- Latin America12.6
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 81 | 76 | 75 | 97 | 75 | 93 | 83 |
| Roche Diagnostics | 81 | 78 | 81 | 78 | 81 | 84 | 81 |
| Thermo Fisher Scientific | 88 | 65 | 88 | 80 | 71 | 70 | 77 |
| Siemens Healthineers | 72 | 79 | 81 | 69 | 72 | 73 | 74 |
| Becton Dickinson and Company (BD) | 61 | 69 | 64 | 60 | 53 | 55 | 60 |
| Quidel Corporation | 47 | 50 | 47 | 71 | 67 | 64 | 58 |
| Bio-Rad Laboratories | 63 | 59 | 62 | 64 | 56 | 60 | 61 |
| Hologic Inc. | 51 | 53 | 47 | 54 | 49 | 44 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Roche Diagnostics
- Thermo Fisher Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Roche Diagnostics | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Thermo Fisher Scientific | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| Siemens Healthineers | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Becton Dickinson and Company (BD) | − | ✓ | ◐ | ◐ | − | ◐ |
| Quidel Corporation | − | ◐ | − | ◐ | − | ◐ |
| Bio-Rad Laboratories | − | ◐ | − | − | ◐ | − |
| Hologic Inc. | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories83
2Roche Diagnostics81
3Thermo Fisher Scientific77
4Siemens Healthineers74
5Bio-Rad Laboratories61
6Becton Dickinson and Company (BD)60
7Quidel Corporation58
8Hologic Inc.50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesRoche Diagnostics
Challenger2
Strong scale, closing on the leaders.
Thermo Fisher ScientificSiemens Healthineers
Contender3
Focused players with pockets of strength.
Becton Dickinson and Company (BD)Quidel CorporationBio-Rad Laboratories
Niche1
Specialists in a single segment or region.
Hologic Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across SARS-Cov-2 Test Kits Market — a $90M beachhead inside a $1.37B market.
Beachhead (SOM)$90Mobtainable near-term
Serviceable (SAM)$552Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Molecular (RT-PCR) Test Kits
Best fit — highest urgency & budget in Test Type.
Economic buyer75 fit
Antigen Test Kits
Strong fit — clear ROI and a fast path to value.
End user69 fit
Antibody (Serology) Test Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sample Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win SARS-Cov-2 Test Kits Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified20%
Evaluation13%
Closed-won7%
$16.2KCAC
$79KLTV
4.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
SARS-Cov-2 Test Kits Market is a resilient opportunity — $4.08B by 2033, compounding at 4.1%.
TAM · 2025$2.96Btoday
TAM · 2033$4.08Bforecast
CAGR4.1%2027–2033
Cumulative$31.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.08BTotal addressable market
SAM$1.49BServiceable available market
SOM$317MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.1% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.08BLarge & growingTAM by 2033 at 4.1% CAGR
$1.49BServiceable nowreachable with today’s model
$317MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.18BBear2.7% CAGR
$4.08BBase4.1% CAGR
$5.23BBull5.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
SARS-Cov-2 Test Kits Market — a $2.92B market by 2033. Plan: grow share from 9.6% to 18.0%.
Market size · 2033$2.92Btotal addressable
Market CAGR10.0%2027–2033
Target share18.0%from 9.6% today
Revenue ambition$525Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.6% | 18.0% | On track |
| Revenue | $255M | $525M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.2% | 39.3% | At risk |
| Customer retention | 85.8% | 95.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $63M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the SARS-Cov-2 Test Kits Market conversation — a $9.66B market you can size, segment and defend in minutes.
Market size · 2033$9.66Btotal opportunity
Growth10.7%CAGR to 2033
Addressable buyers993+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 2 mopayback period
$86K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Abbott LaboratoriesRoche DiagnosticsThermo Fisher ScientificSiemens HealthineersBecton Dickinson and Company (BD)Quidel CorporationBio-Rad LaboratoriesHologic Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your SARS-Cov-2 Test Kits Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
SARS-Cov-2 Test Kits Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →SARS-CoV-2 IgM and IgG Antibody Test Kit(Colloidal Gold Method) Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportSARS-CoV-2 IgG (RBD) ELISA Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportSARS-CoV-2 Antigen Test Kit Market
Market size, share, segmentation and regional forecast.
$774M market · 2025 base year
View reportSarsaparilla Extract Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportSarpogrelate Hydrochloride Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportSarolaner Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportSarecycline Market
Market size, share, segmentation and regional forecast.
$619M market · 2025 base year
View reportSarcosine Methyl Ester Hydrochloride Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportSarcopenia Treatment Supplements Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportSarcopenia Therapeutic Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportSarcopenia Supplement Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportSarcoma Treatment Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.